June 3, 2022 — Combination chemoimmunotherapy with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously ...
May 12, 2022 — A study investigates the reasons for decreasing remission rates for patients with non-Hodgkin lymphoma treated with chimeric antigen receptor-T cell therapy (CAR-T cell ...
Apr. 28, 2022 — Researchers identify gene expression signatures in different types of lymph nodes cells that play an active role in the development of ...
Feb. 28, 2022 — Researchers have shared a comprehensive multiomics study from a rare cohort of 56 patients with transformed CTCL and identified several genomic alterations and oncogenic programs that may be ...
Jan. 12, 2022 — There are myriad reasons why cancers develop. By studying genes which are altered in people with lymphoma, a multidisciplinary team of researchers has identified a key mechanism involved in disease ...
Jan. 3, 2022 — Aggressive and relatively common lymphomas called diffuse large B cell lymphomas (DLBCLs) have a critical metabolic vulnerability that can be exploited to trick these cancers into starving ...
Aug. 24, 2021 — New research has revealed a new fundamental feature of aggressive B-cell lymphomas which could open the door to further research into early detection and treatment of the ...
July 1, 2021 — More than 9 of 10 patients with cancer showed good immune response to the COVID-19 mRNA vaccines after receiving both doses, but subsets of high-risk patients did not, according to a new ...
Apr. 11, 2021 — Early results from a new, pioneering chimeric antigen receptor (CAR) T cell immunotherapy trial found using a bilateral attack achieves a more robust defense and helps avoid ...
Dec. 17, 2020 — The researchers discovered that cancer immunotherapies that make use of immune system cells such as T cells and CAR-T cells kill not only tumor cells that express the drugs' target, but also ...
Dec. 16, 2020 — Scientists at Scripps Research have demonstrated a promising new strategy for treating lymphomas, a group of cancers that begin in infection-fighting cells of the immune system called ...
Dec. 5, 2020 — A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical ...
Oct. 11, 2020 — A research team hsd discovered that certain exosomes can effectively control Epstein-Barr virus-associated tumors and induce T-cell anti-tumor immunity. The novel findings provide insights into new ...
Sep. 28, 2020 — The immune system will memorize the pathogen after an infection and can therefore react promptly after reinfection with the same pathogen. Now, scientists have deciphered new details of this ...
Aug. 18, 2020 — Researchers describe a novel acidic niche within lymph nodes that plays an integral role in regulating T cell ...
May 30, 2020 — Although lymphoma is one of the most common types of blood cancer, it has a rare subtype for which no effective treatment regimens are known. For the first time, researchers have conducted clinical ...
May 12, 2020 — A research team has developed a novel anti-Epstein-Barr virus (EBV) drug that can selectively disrupt a viral protein produced by EBV, leading to the shrinkage of tumors caused by the virus. It is ...
May 5, 2020 — In an international collaboration, researchers have mapped the lymph node lymphatic vessels in mice and humans down to the level of individual cells. The results may eventually help scientists to ...
Apr. 23, 2020 — Scientists have identified a key mechanism that tumor cells use to take advantage of and avoid detection from the immune system. Targeting this mechanism offers a new therapeutic strategy for cancers ...
Feb. 20, 2020 — Researchers have revealed a new vulnerability in lymphomas that are driven by one of the most common cancer-causing changes in cells. The team hopes that this could be a new target for treating a ...